Developers of cancer therapeutics are exploring different possibilities. Strategies include narrow-front and broad-front attacks—for both, the necessary armaments are in the works. At the same time, the developers are interested in limiting collateral damage and fending off counterattacks. That is, they hope to prevent side effects and suppress drug resistance.